Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Pharmacokinetics, Safety and Tolerability of Baloxavir Marboxil in Healthy Chinese Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chinese participants must have Chinese parents and grandparents, all of whom were born in China.~* Healthy status as defined by absence of evidence of any active or chronic disease~* Participants whose body weight is ≥50 to \<80 kg and body mass index is ≥18.5 to \<26 kg/m2~Exclusion Criteria:~* Participants with a history of stomach, vagus nerve, or intestinal surgery (except for appendectomy)~* Participants who have a history of allergic symptoms including food allergy (Note: Non-active allergic rhinitis will be allowed)~* Participants who require chronic drug therapy or those who have used drugs within 3 days prior to screening or within 14 days prior to Day -1~* Participants who have used alcohol-containing, caffeine-containing, grapefruit containing, or St. John's wort-containing products within 72 hours prior to Day -1~* Participants who have used tobacco- or nicotine-containing products within 24 weeks prior to screening~* Participants who have donated \> 400 mL of blood within 12 weeks or \> 200 mL of blood within 4 weeks prior to screening, or have donated any amount of blood between screening and Day -1

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- Baloxavir Marboxil 40 mg (Type: EXPERIMENTAL): None
- Baloxavir Marboxil 80 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).